Results 71 to 80 of about 1,026 (172)

Changing Pattern of HDV Infection in Italy Over 40 Years; the Current Scenario and the Impending Challenge

Journal of Viral Hepatitis, Volume 33, Issue 4, April 2026.
ABSTRACT Since the initial description of HDV, in the last four decades Italy has witnessed a profound decline of the infection driven by HBV vaccination, contrasted however by the reconstitution of a viral reservoir through migratory flows from endemic HDV areas; in parallel, the medical scenario has changed, resulting in different clinical outcomes ...
Gian Paolo Caviglia, Tommaso Stroffolini
wiley   +1 more source

Prospects for Controlling Hepatitis B Globally

Pathogens
Infection with the hepatitis B virus (HBV) is highly prevalent globally. Over 250 million people suffer from chronic hepatitis B, and more than 800,000 patients die each year due to hepatitis B complications, including liver cancer.
Vicente Soriano, Víctor Moreno-Torres, Ana Treviño, Fernando de Jesús, Octavio Corral, Carmen de Mendoza   +5 more
doaj   +1 more source

Prevalence and Risk Factors of Elevated Alanine Aminotransferase (ALT) in 2382 Treatment‐naïve HBV/HDV Co‐Infected Patients

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT Background Chronic hepatitis D (CHD) causes severe chronic hepatitis. Knowledge is limited about factors correlating with ALT in treatment‐naïve patients with CHD. This study analysed the pattern and determinants of ALT elevation in a large cohort of patients with CHD, including young adults, compared to propensity score‐matched (PSM) patients
Habiba Kamal, Ganbolor Jargalsaikhan, Sanjaasuren Enkhtaivan, Karin Lindahl, Hannes Hagström, Daniel Bruce, Michael Ingre, Bekhbold Dashtserenx, Oyungerel Lkhagva‐Ochir, Tuvshinjargal Ulziibadrakh, Andreas Bungert, Heiner Wedemeyer, Naranjargal B. Dashdorj, Soo Aleman   +13 more
wiley   +1 more source

Exploring Predictive Factors for Bulevirtide Treatment Response in Hepatitis Delta-Positive Patients

Biomedicines
Background: Hepatitis delta virus (HDV) infection represents the most severe form of viral hepatitis and is a significant global health challenge. Bulevirtide (BLV) is a novel therapeutic treatment that has resulted in variable response rates in HBV/HDV ...
Verdiana Zulian, Leonidas Salichos, Chiara Taibi, Silvia Pauciullo, Levi Dong, Gianpiero D’Offizi, Elisa Biliotti, Alessia Rianda, Luigi Federici, Angela Bibbò, Martina De Sanctis, Fiona McPhee, Anna Rosa Garbuglia   +12 more
doaj   +1 more source

Bulevirtide Treatment of Hepatitis Delta Virus Infection in a Kidney Transplant Recipient: A Case Report

OBJECTIVES: Hepatitis delta virus infection poses a significant challenge in solid-organ transplant recipients due to its aggressive nature and limited therapeutic options.
Piccione A., Carrano R., Schettino E., Pinchera B., Cuccurullo F., Gentile I., Salemi F., Buonomo A. R.   +7 more
core   +1 more source

Bulevirtide plus Tenofovir Disoproxil Fumarate Improves Liver Function in HDV/HBV Related Cirrhosis after Virological Response: A Case Report

, 2022
Hepatitis D virus (HDV) globally affects nearly 5% of people with chronic hepatitis B virus (HBV) infection. Bulevirtide (BLV) is an HDV/HBV entry inhibitor recently approved for adult patients with chronic hepatitis delta (CHD).
Nikolaos Papadopoulos, Periklis Apostolopoulos, Panagiotis Tsibouris, Ioannis Braimakis   +3 more
core   +1 more source

Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis—A real-world case series [PDF]

Background and Aims: Chronic hepatitis D is the most debilitating form of viral hepatitis frequently progressing to cirrhosis and subsequent decompensation. However, the HDV entry inhibitor bulevirtide is only approved for antiviral treatment of patients
Gödiker, Juliana, Sprinzl, Kathrin, Wedemeyer, Heiner, Wiegand, Johannes, Herta, Toni, Berg, Christoph P., Degasperi, Elisabetta, Soffredini, Roberta, Lampertico, Pietro, Reiberger, Thomas, Deterding, Katja, Schlevogt, Bernhard, Jachs, Mathias, Maasoumy, Benjamin, Geier, Andreas, Grottenthaler, Julia M., Reiter, Florian P., Dietz-Fricke, Christopher, Zeuzem, Stefan   +18 more
core   +1 more source

Triple Burden of HIV, HBV and HDV in Adults with Childhood Parenterally Acquired Infections: A Romanian Single-Center Study

Pathogens
Background: Co-infections with HIV, HBV, and HDV pose significant public health challenges, especially in populations exposed parenterally. Romania hosts a unique pediatric HIV cohort of individuals born 1987–1995 who acquired HIV iatrogenically.
Manuela Arbune, Alina-Viorica Iancu, Monica-Daniela Padurariu-Covit, Alina Plesea-Condratovici, Anca-Adriana Arbune, Catalin Plesea-Condratovici   +5 more
doaj   +1 more source

Effectiveness, Safety and Patient-Reported Outcomes of Bulevirtide Therapy in Chronic Hepatitis Delta: Real-World Evidence From a Prospective Observational Study

: Chronic hepatitis delta (CHD) is the most severe form of viral hepatitis and is associated with accelerated progression to cirrhosis and liver failure.
Pasin, Francesca, Simioni, Paolo, Battistella, Sara, Tonon, Marta, Barbaro, Francesco, Giunco, Elisabetta Mariavittoria, Berti, Giacomo, Cadore, Alessandro, Scribano, Laura, Gambato, Martina, Burra, Patrizia, Russo, Francesco Paolo, Sasset, Lolita, Mengato, Daniele, Romano, Antonietta, Cattelan, Annamaria, Venturini, Francesca, Zanaga, Paola, Zappitelli, Teresa   +18 more
core   +1 more source

HBV, HCV, and HDV Triple-Infection—A Therapeutic Challenge

Diseases
Purpose: This article aims to harmonize the current data from the literature, describe baseline severity, and discuss potential treatment considerations for cases of triple infection.
Alexia Anastasia Stefania Balta, Mariana Daniela Ignat, Raisa Eloise Barbu, Liliana Baroiu, Lavinia Alexandra Moroianu, Valerii Lutenco, Valentin Bulza, Mihaela Patriciu, Caterina Dumitru, Mihaela Debita   +9 more
doaj   +1 more source